A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change (NCT07239167) | Clinical Trial Compass
By InvitationNot Applicable
A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change
Taiwan500 participantsStarted 2025-06-05
Plain-language summary
This prospective cohort study collected baseline data and followed up obese patients at their first visit to a weight loss clinic. The study examined the impact of various predictors and biomarkers on weight loss outcomes, aiming to establish an evidence-based foundation for personalized weight loss treatment.
Participants underwent a battery of measurements and questionnaires, including height, weight, waist circumference, blood pressure, blood tests, and questionnaires addressing diet, exercise, stress, sleep, measure handgrip strength ,and psychological well-being.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Adults aged 18 years or older, regardless of gender.
. Body mass index (BMI) ≥ 27 kg/m², or ≥ 24 kg/m² with one or more obesity-related comorbidities.
. Willing to undergo any form of weight loss intervention.
. Able to read and understand Chinese, willing to complete questionnaires, blood tests, and follow-up follow-up.
. Voluntarily consent to participate and be willing to complete the subject consent form.
Exclusion criteria
. Pregnant or breastfeeding women.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Baseline data were collected and followed up during the subjects' initial visit to the weight loss clinic to establish an evidence-based basis for personalized weight reduction treatment.
Timeframe: Weight changes of subjects after 24 weeks, 48 weeks, 72 weeks, and 96 weeks.
. Individuals with significant mental illness (e.g., schizophrenia, severe depression) or cognitive impairment that may affect their ability to consent or cooperate with the study.
. Individuals with severe organ dysfunction (e.g., end-stage renal disease, cirrhosis, congestive heart failure, etc.).
. Individuals taking medications that significantly affect their weight (e.g., long-term steroids or antipsychotics) and cannot be discontinued.
. Individuals deemed unsuitable for participation in this study by the study leader (e.g., individuals who are expected to be unable to complete follow-up).